Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate AGS-003 has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the first half of 2014.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/26/13 | $42,500,000 | Series E |
Aurora Funds Caisse de depot et placement de Quebec Forbion Capital Partners Green Cross Intersouth Partners Lumira Capital Morningside Group Pharmstandard International | undisclosed |
| 11/21/13 | $17,500,000 | Series E-1 |
Aurora Funds Caisse de depot et placement de Quebec Forbion Capital Partners Green Cross Intersouth Partners Lumira Capital Morningside Group Pharmstandard International | undisclosed |
